Gilead Sciences has now formally closed its previously disclosed deal to acquire Tubulis GmbH, the Germany-based clinical-stage biopharmaceutical company dedicated to developing the next generation of antibody-drug conjugates (ADCs).
With this acquisition, Gilead is not only broadening its oncology expertise Much, but also leveraging Tubulis’ sophisticated ADC platform and pipeline that feature highly selective tumor-targeted drug release as the basis for improved cancer therapy. Tubulis’ unique technologies are intended to manufacture ADCs with superior biophysical traits, Because of this leading to a higher degree of tumor-specific drug exposure and the possibility of an extended anti-tumor effect.
Through this deal, Gilead is gaining the rights to Tubulis’ main clinical programs, among them TUB-040, a NaPi2b-targeting topoisomerase-I inhibitor (TOPO1i) ADC which is currently showing promising results in platinum-resistant ovarian cancer. The takeover also comprises TUB-030, a 5T4-targeting ADC, which is being studied in multiple solid tumor indications. These new items will continue to support Gilead’s expanding ADC portfolio and its overall oncology strategy.
Also Read: QIAGEN and NVIDIA Partner to Accelerate AI-Driven Drug Discovery
“We look forward to welcoming the Tubulis team to Gilead and building on the significant progress they have made in advancing novel ADC technology for people living with cancer,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “Our two-year collaboration with Tubulis gave us strong conviction in their team, their programs and their technologies. We will now combine our strengths in service of providing new options for some of the most challenging forms of disease.”
In accordance with the agreement, Gilead purchased all existing equity stakes in Tubulis at a valuation of $3.15 billion upfront, on a cash-free, debt-free basis. Besides the upfront payment, the transaction incorporates milestone-dependent payments of up to $1.85 billion which may be realized upon development and commercial accomplishments.
Post the acquisition, the Tubulis workforce will remain in Munich Germany where the business will set up the Tubulis ADC Innovation Center. This center will operate as a main location devoted to boosting research, production, and clinical development capabilities of next-generation ADCs, Because of this, promoting the evolution of targeted cancer therapies.
